表紙
市場調査レポート

Pharming Group N.V.の製品パイプライン分析

Pharming Group N.V. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 200990
出版日 ページ情報 英文 35 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
Pharming Group N.V.の製品パイプライン分析 Pharming Group N.V. - Product Pipeline Review - 2015
出版日: 2015年05月29日 ページ情報: 英文 35 Pages
概要

Pharming Group N.V.はオランダに本社を置くバイオ製薬企業で、遺伝性疾患、加齢性障害、外科手術による出血、外傷性出血などのアンメットニーズに対応する治療用タンパク質および栄養剤の開発、製造、商品化を行っています。

当レポートでは、Pharming Group N.V.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Pharming Group N.V.の基本情報

  • Pharming Group N.V.の概要
  • 主要情報
  • 企業情報

Pharming Group N.V.:R&Dの概要

  • 主な治療範囲

Pharming Group N.V.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Pharming Group N.V.:パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Pharming Group N.V.:薬剤プロファイル

  • C1 esterase inhibitor (recombinant)
  • Recombinant Enzyme to Replace Alpha Glucosidase for Pompe Disease
  • Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease
  • Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease
  • Recombinant Enzyme to Replace Factor IX for Hemophilia B
  • Recombinant Human Collagen Type 1
  • rhFactor VIII

Pharming Group N.V.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Pharming Group N.V.:最新のパイプライン情報

Pharming Group N.V.:開発休止中のプロジェクト

Pharming Group N.V.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル

Pharming Group N.V.:企業理念

Pharming Group N.V.:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07100CDB

Summary

Global Markets Direct's, 'Pharming Group N.V. - Product Pipeline Review - 2015', provides an overview of the Pharming Group N.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharming Group N.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Pharming Group N.V. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Pharming Group N.V.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Pharming Group N.V.'s pipeline products

Reasons to buy

  • Evaluate Pharming Group N.V.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Pharming Group N.V. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Pharming Group N.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Pharming Group N.V. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharming Group N.V.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Pharming Group N.V. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Pharming Group N.V. Snapshot
    • Pharming Group N.V. Overview
    • Key Information
    • Key Facts
  • Pharming Group N.V. - Research and Development Overview
    • Key Therapeutic Areas
  • Pharming Group N.V. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Pharming Group N.V. - Pipeline Products Glance
    • Pharming Group N.V. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Pharming Group N.V. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Pharming Group N.V. - Drug Profiles
    • C1 esterase inhibitor (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Alpha Glucosidase for Pompe Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Factor IX for Hemophilia B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Replace Factor VIII for Hemophilia A
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pharming Group N.V. - Pipeline Analysis
    • Pharming Group N.V. - Pipeline Products by Target
    • Pharming Group N.V. - Pipeline Products by Route of Administration
    • Pharming Group N.V. - Pipeline Products by Molecule Type
    • Pharming Group N.V. - Pipeline Products by Mechanism of Action
  • Pharming Group N.V. - Recent Pipeline Updates
  • Pharming Group N.V. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • fibrinogen
  • Pharming Group N.V. - Company Statement
  • Pharming Group N.V. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Pharming Group N.V., Key Information
  • Pharming Group N.V., Key Facts
  • Pharming Group N.V. - Pipeline by Indication, 2015
  • Pharming Group N.V. - Pipeline by Stage of Development, 2015
  • Pharming Group N.V. - Monotherapy Products in Pipeline, 2015
  • Pharming Group N.V. - Phase II, 2015
  • Pharming Group N.V. - Preclinical, 2015
  • Pharming Group N.V. - Discovery, 2015
  • Pharming Group N.V. - Pipeline by Target, 2015
  • Pharming Group N.V. - Pipeline by Route of Administration, 2015
  • Pharming Group N.V. - Pipeline by Molecule Type, 2015
  • Pharming Group N.V. - Pipeline Products by Mechanism of Action, 2015
  • Pharming Group N.V. - Recent Pipeline Updates, 2015
  • Pharming Group N.V. - Discontinued Pipeline Products, 2015
  • Pharming Group N.V., Subsidiaries

List of Figures

  • Pharming Group N.V. - Pipeline by Top 10 Indication, 2015
  • Pharming Group N.V. - Pipeline by Stage of Development, 2015
  • Pharming Group N.V. - Monotherapy Products in Pipeline, 2015
  • Pharming Group N.V. - Pipeline by Top 10 Target, 2015
  • Pharming Group N.V. - Pipeline by Top 10 Route of Administration, 2015
  • Pharming Group N.V. - Pipeline by Top 10 Molecule Type, 2015
  • Pharming Group N.V. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top